drugset / Trial / NCT07418372
Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
Phase 1/2
Not yet recruiting
660 enrolled
Institute of Medical Biology, Chinese Academy of Medical Sciences
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomized, double-blinded, parallel-controlled phase I/II clinical trial to evaluate the safety and preliminary immunogenicity of the Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (reduced antigen content) in subjects aged 6 years and above.
Timeline
- Start
- 2026-03-12
- Primary completion
- 2026-08-31
- Completion
- 2027-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | — |
| Subject | Tetanus, Diphtheria and Acellular Component Pertussis Vaccine Adsorbed (Reduced Antigens Content) | Vaccine | 0.5 ml | — |
| Comparator | Tetanus, Diphtheria and Acellular Pertussis Vaccine | Vaccine | 0.5 ml | — |